Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Nivolumab (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 28 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 04 Aug 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2026.
- 04 Aug 2023 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2026.